Fox Chase Cancer Center Welcomes Dr. Samuel Ivan

Samuel Ivan
Samuel J. Ivan, MD, an Assistant Professor in the Department of Urology and the Fox Chase – Temple Urologic Institute

PHILADELPHIA (November 20, 2025) — Fox Chase Cancer Center is pleased to announce the hiring of Samuel J. Ivan, MD, as an Assistant Professor in the Department of Urology and the Fox Chase – Temple Urologic Institute. In addition to seeing patients at the main campus and Fox Chase – Voorhees, Ivan will also provide services at Temple Health – Jeanes Campus and Temple Health – Main Campus.

Ivan recently completed a Reconstructive and Prosthetic Urology Fellowship at Fox Chase. He completed his urology residency at Carolinas Medical Center in Charlotte, where he also served in several departmental leadership roles and was recognized for excellence in both teaching and research.

Ivan earned his medical degree from the University of Toledo College of Medicine, where he was inducted into the Alpha Omega Alpha Honor Medical Society and received the Edward F. Ockuly Award for outstanding achievement in clinical urology. He completed his undergraduate studies in molecular biology at Grove City College.

An active member of the American Urological Association (AUA), Ivan has held multiple national leadership roles within the AUA, recently serving as chair of the AUA Residents and Fellows Committee. He has presented his research extensively at national and international meetings, with focuses on surgical outcomes after urinary diversion and prosthetic surgery, surgical education innovation, and opioid stewardship in urologic surgery.

Ivan has authored numerous peer-reviewed publications and contributed to textbooks on prosthetic and reconstructive urology. His recent work has appeared in such leading journals as Urologic Oncology and The Journal of Urology.

Ivan has surgical expertise in both open and robotic approaches to genitourinary reconstruction. He will treat conditions including urethral stricture, male urinary incontinence, erectile dysfunction, Peyronie’s disease, buried penis, radiation cystitis, and hydronephrosis or kidney blockage.

Ivan began his tenure at Fox Chase on October 1.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427